Where does ADMA Biologics's cash flow data come from?

Every line is extracted from ADMA Biologics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

ADMA Biologics ADMA Cash Flow Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Net income	$165.35M-20.0%	$146.93M-25.7%	$209.45M+207%	$208.93M+501%	$206.77M+5,773%
Depreciation and amortization	$7.8M+1.3%	$7.9M+2.6%	$7.9M+11.6%	$7.8M+7.3%	$7.7M+3.1%
Stock-based compensation	$21.73M+35.0%	$20.03M+47.1%	$20.07M+102%	$18.2M+116%	$16.1M+123%
Deferred income taxes	$10.89M+113%	$11.02M+113%	-$74.43M—	-$79.24M—	-$80.86M—
Impairment charges	$0—	$0—	$0—	$0—	$0—
Gain (loss) on sale of assets	$7.99M+9,728%	-$9K+91.5%	-$74K+28.2%	-$82K+56.4%	-$83K+55.6%
Change in accounts receivable	$36.45M—	$108.43M—	——	——	——
Change in inventories	$49.91M+1,000%	$36.23M+1,456%	$24.87M+186%	$11.65M-35.4%	-$5.54M-140%
Change in accounts payable	——	——	——	$14.97M+319%	$3.85M-15.7%
Change in accrued liabilities	$12.72M+697%	$5.21M+400%	$999K+137%	$1.03M+143%	-$2.13M-122%
Change in other assets	——	——	——	——	——
Change in other liabilities	-$969K+60.8%	-$1.28M-11.8%	-$1.18M-9.1%	-$2.21M-2,666%	-$2.47M-3,485%
Other working capital changes	——	——	——	——	——
Amortization of intangible assets	$176K-20.0%	$146K-62.4%	$120K-77.9%	$110K-84.2%	$220K-70.1%
Debt issuance costs and discount amortization	$718K-19.1%	$717K-24.6%	$739K-48.3%	$821K-56.8%	$888K-62.4%
Net cash from operating activities	$128.32M+26.8%	$50.4M-57.5%	$64.97M-24.5%	$76.71M+5.1%	$101.22M+375%
Capital expenditures	$20.42M+93.0%	$22.58M+174%	$24.25M+264%	$10.94M+71.8%	$10.58M+105%
Purchases of intangible assets	$350K-2.8%	$316K-11.2%	$124K-78.1%	$166K-68.3%	$360K+60.0%
Acquired in-process research and development	$6.53M+198%	$4.76M+163%	$3.78M+68.0%	$2.66M0.0%	$2.19M-25.2%
Net cash from investing activities	-$14.77M-35.1%	-$21.89M-155%	-$24.37M-237%	-$11.1M-61.0%	-$10.93M-103%
Repurchases of common stock	——	——	——	——	——
Proceeds from issuance of common stock	$3.47M+474%	$2.98M—	-$4.5M-176%	$805K-9.3%	-$928K-190%
Net cash from financing activities	-$47.07M+26.4%	-$44.07M+24.4%	-$65.98M+0.4%	-$63.62M-57.5%	-$63.98M-59.9%
Net increase (decrease) in cash	——	——	——	——	$27.84M+163%
Interest paid	$7.65M-40.4%	$9.08M-14.9%	$10.97M-8.1%	$11.78M-8.4%	$12.83M-9.1%
Income taxes paid	$19.77M—	$19.68M—	$14.84M—	$14.73M—	——
Amortization Of Debt Discount Premium	$718K-19.1%	$717K-24.6%	$739K-48.3%	$821K-56.8%	$888K-62.4%
Amortization Of License Revenue	-$143K0.0%	-$143K0.0%	-$143K0.0%	-$143K0.0%	-$143K0.0%
Gain/(loss) on dispositions, net	-$51K+38.6%	-$9K+91.5%	-$74K+28.2%	-$82K+56.4%	-$83K+55.6%
Gain (Loss) on Disposition of Assets	——	——	——	——	——
Impairment charges for facilities consolidation	——	$0—	$0—	$0—	$0—
Increase (Decrease) in Deferred Income Taxes	——	-$11.02M-113%	$12.81M-79.7%	$36.63M-13.1%	$60.46M+187%
Increase Decrease In Deposits And Other Assets	-$538K+51.8%	-$279K-1,760%	-$165K+91.3%	$223K+111%	-$1.12M-685%
Increase (Decrease) in Prepaid Expense and Other Assets	——	——	——	——	——
Inventory write-downs	——	——	——	——	——
Net income	——	——	——	——	——
Medford settlement proceeds (Note A)	——	——	——	——	——
Payments to Acquire Intangible Assets	$350K-2.8%	$316K-11.2%	$124K-78.1%	$166K-68.3%	$360K+60.0%
Proceeds From Sale Of Property Held For Sale	——	——	——	——	——
Taxes Paid On Vested Restricted Stock Units	$7.38M-24.1%	$9.55M+92.1%	$10.03M+115%	$10.22M+175%	$9.72M+199%
Class Of Warrant Or Right Exercised	——	——	——	——	——
Cost Of Revenue	$197.45M-9.4%	$217.41M+5.1%	$221.28M+13.5%	$222.86M+25.8%	$217.84M+28.4%
Gross Profit	$312.42M+29.3%	$292.77M+33.3%	$267.28M+49.8%	$251.32M+78.2%	$241.54M+128%
Income before provision for income taxes	$206.33M+46.6%	$182.66M+45.3%	$155.78M+85.6%	$145.01M+261%	$140.76M+5,167%
Effective Income Tax Rate Reconciliation, Tax Credit, Amount	——	$1.88M—	——	——	——
Interest Expense, Nonoperating	$7.24M-40.4%	$7.11M-49.0%	$8.36M-51.7%	$10.19M-49.2%	$12.14M-46.2%
Marketing and business development	——	$3.1M+14.8%	$3M+5.3%	$2.9M-3.3%	$2.8M-11.1%
Other Income - Net	-$8.5M+24.6%	-$8.79M+33.8%	-$11.24M+49.2%	-$10.63M+66.5%	-$11.28M+72.4%
Purchased Services and Other	$4.61M+1.9%	$4.84M+13.9%	$4.99M—	$4.74M—	$4.53M—
Stock repurchased, excise tax	——	——	——	——	——
Issuance of warrants	——	——	——	——	——
Total state income taxes, net of refunds	——	$2.09M—	——	——	——
Income Taxes Paid, Net	——	$19.68M—	——	——	——
Free cash flow	$107.9M+19.1%	$27.82M-74.8%	$40.73M-48.7%	$65.77M-1.3%	$90.64M+462%
Free cash flow	$107.9M+19.1%	$27.82M-74.8%	$40.73M-48.7%	$65.77M-1.3%	$90.64M+462%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does ADMA Biologics's cash flow data come from?: Every line is extracted from ADMA Biologics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.